Ancion, A., Tridetti, J., Nguyen Trung, M.‐L., Oury, C., and Lancellotti, P. (2020) Serial heart rate measurement and mortality after acute heart failure. ESC Heart Failure, 7: 103--106. 10.1002/ehf2.12530.

Introduction {#ehf212530-sec-0004}
============

Heart failure (HF) poses a unique medical burden of high morbidity and mortality. The continued high mortality rate for patients hospitalized with acute HF provides a compelling indication for accurate risk stratification to potentially improve individual management and hospital outcome. Elevated resting heart rate (HR) is associated with worse outcomes in chronic HF but little is known about the clinical value of serial HR measurement during hospital stay after acute HF.[1](#ehf212530-bib-0001){ref-type="ref"}, [2](#ehf212530-bib-0002){ref-type="ref"}, [3](#ehf212530-bib-0003){ref-type="ref"}, [4](#ehf212530-bib-0004){ref-type="ref"} The main aim of the present study was to examine the relationship between resting HR obtained at admission at Day 4 and at discharge and long‐term mortality after surviving from acute HF.

Methods {#ehf212530-sec-0005}
=======

The present study collected detailed hospitalization data from computerized medical records of patients presenting with acute HF at CHU of Liège, Belgium, between January 2010 and December 2012. Patients (*n* = 1611) were eligible for the first round of selection if they were \> 18 years of age, had a suspected diagnosis of HF, and were alive 24--36 h after admission. After a second round of selection, 899 patients with ≥1 following criteria were further disqualified respiratory support, cardiogenic shock, acute coronary syndrome, resting HR \< 40 b.p.m., inotropic support, primary valvular heart disease, permanent pacemaker pacing, arrhythmias, infectious/inflammatory disease (C‐reactive protein \>10 mg/L), end‐stage renal failure requiring dialysis, and cancer. At the end of the selection process, we kept 672 patients discharged from hospital after management of acute HF in whom serial HR measurement was reported in the medical file (no data on electrocardiogram morphology and adaptation of medication during the hospital stay were obtained). The association between HR obtained at admission at Day 4 and at discharge, and long‐term mortality was then examined retrospectively. The diagnosis of HF was based upon the following conditions to be satisfied symptoms typical of HF, signs of HF, either reduced left ventricular ejection fraction or diastolic dysfunction with structural heart disease and increased N terminal pro brain natriuretic peptide (\>125 pg/ml, median: 4954 pg/ml, 25‐75th percentile 2362--12194 pg/ml). HR was derived from electrocardiogram and was defined as the first reported HR in the medical record. Hospital HR was categorized into tertiles. A logistic model was applied to identify significant predictors of 1 year mortality. All statistical analyses were performed with [statistica]{.smallcaps} Version 10 (StatSoft Inc, Tulsa, Okla). In order to avoid overfitting the multivariable model, we have only included significant univariable parameters. Values of *P* \< 0.05 were considered significant. All authors have read and agree to the manuscript as written. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution\'s human research committee.

Results {#ehf212530-sec-0006}
=======

All patients examined were in sinus rhythm. HR was 86 ± 17 b.p.m. (first tertile: 75 b.p.m., third tertile 97 b.p.m.) at admission, 76 ± 14 b.p.m. (first tertile: 67 b.p.m., third tertile 85 b.p.m.) at Day 4, and 72 ± 11 b.p.m. (first tertile: 64 b.p.m., third tertile 80 b.p.m.) at discharge (13 ± 6 days). At 1 year follow up, 60 patients died. Those patients were significantly older (75 ± 11 vs. 71 ± 12 years; *P* = 0.027), had more frequently a history of ischemic cardiomyopathy (*n* = 34/60, *P* = 0.012) and of chronic obstructive pulmonary disease (*n* = 26/60, *P* = 0.027), had higher admission N terminal pro brain natriuretic peptide (7647 ± 7964 vs. 14572 ± 21600; *P* = 0.027), had lower systolic and diastolic blood pressures (*P* \< 0.05), haemoglobin level (12.2 ± 2.2 vs. 10.6 ± 2.2 g/dl; *P* = 0.005), albumin level (37.1 ± 4.1 vs. 35.2 ± 4.3 g/dl; *P* = 0.003) and estimated glomerular filtration rate (60 ± 28 vs. 47 ± 21 ml/min/1.73 m^2^; *P* = 0.0017) (*Table* [1](#ehf212530-tbl-0001){ref-type="table"}). There were no significant differences between survivors and nonsurvivors in left ventricular ejection, the use of beta‐blocker and angiotensin‐converting enzyme‐inhibitor, and the rate of comorbidities (hypertension, diabetes) (*P*=NS, for all). HR at admission was not significantly associated with 1 year mortality \[odds ratio (OR), 1.01; 95% confidence interval (CI), 0.90--1.03; *P* = 0.20\], whereas HR at Day 4 (OR 1.05; 95%CI, 1.03--1.08; *P* \< 0.0001) and at discharge (OR 1.09; 95%CI, 1.06--1.11; *P* \< 0.0001) were predictive of the outcome. There was also a significant increase in 1 year mortality for HRs\>85 b.p.m. at Day 4 (OR 3.2; 95% CI, 1.88--5.48; *P* \< 0.0001) and \> 80 b.p.m. at discharge (OR 3.1; 95% CI, 1.98--4.89; *P* \< 0.0001) (*Figure* [1](#ehf212530-fig-0001){ref-type="fig"}). Of note, when receiver operating characteristic curve analysis was used for predicting 1 year mortality, the best cut‐off value for HR at Day 4 was 82 b.p.m. (AUC 0.77, 95%CI 0.74--0.80, sensitivity 64%, specificity 82%), and for HR at discharge was 78 b.p.m. (AUC 0.73, 95% CI 0.69--0.76, sensitivity 68%, specificity 68%). *Table* [2](#ehf212530-tbl-0002){ref-type="table"} summarized the multivariable models when HR was included as a continuous variable at Day 4 and at discharge. In the multivariable model that included HR at Day 4 and at discharge, HR at discharge was no longer significant. In the multivariable model that included the third tertile at Day 4 and discharge HR and adjusted for all other significant covariates, haemoglobin (OR 0.74; 95% CI, 0.57--0.95; *P* = 0.019), and HR at Day 4 (OR 2.4; 95% CI, 1.1--5.1; *P* = 0.023) were independently associated with 1 year mortality. When only discharge HR was included, haemoglobin (OR 0.67; 95% CI, 0.53--0.84; *P* = 0.0004) and HR at discharge (OR 2.4; 95% CI, 1.5--3.8; *P* = 0.00053) remained independently associated with 1 year mortality.

###### 

Comparison between baseline characteristics and 1 year mortality

  Variable                                           Whole cohort (*n* = 672)   Survivors (*n* = 612, 91%)   Death (*n* = 60, 9%)   *P*
  -------------------------------------------------- -------------------------- ---------------------------- ---------------------- --------
  Age, years                                         72 ± 12                    71 ± 12                      75 ± 12                0.027
  Heart rate at admission                            86 ± 16                    86 ± 17                      88 ± 14                0.20
  Systolic blood pressure at admission               122 ± 24                   112 ± 19                     123 ± 24               0.028
  Diastolic blood pressure at admission              68 ± 13                    63 ± 12                      68 ± 13                0.036
  Left ventricular ejection fraction, %              45 ± 16                    42 ± 16                      45 ± 16                0.09
  Left ventricular ejection fraction \< 40%, n (%)   283 (42)                   251 (41)                     31 (52)                0.30
  Medical history                                                                                                                   
  Hypertension, n (%)                                314 (47)                   282 (46)                     32 (53)                0.38
  Diabetes, n (%)                                    118 (18)                   107 (17)                     11 (18)                0.96
  COPD, n (%)                                        166 (25)                   144 (24)                     26 (43)                0.027
  Ischaemic cardiomyopathy, n (%)                    274 (41)                   240 (39)                     34 (57)                0.012
  Medications                                                                                                                       
  ACE‐inhibitor                                      245 (36)                   221 (36)                     24 (40)                0.55
  Beta‐blockers                                      269 (40)                   243 (40)                     26 (43)                0.58
  Laboratory findings                                                                                                               
  Haematocrite, %                                    37 ± 6                     35 ± 6.6                     38 ± 6                 0.015
  Haemoglobin, g/dl                                  12.1 ± 2.2                 12.3 ± 2.2                   11.3 ± 2.2             0.005
  Albumin, g/L                                       36.9 ± 4.1                 37.1 ± 4.1                   35.3 ± 4.3             0.003
  Total protein, g/L                                 64.8 ± 6.3                 65 ± 5.8                     65 ± 6.4               0.67
  NT‐proBNP, pg/ml                                   8488 ± 10660               7647 ± 7964                  14572 ± 21600          0.027
  Sodium, mmol/L                                     141 ± 4.2                  141 ± 3.4                    140.7 ± 4.3            0.65
  Creatinine, mg/dl                                  14.0 ± 10.3                13.8 ± 10.3                  16.4 ± 9.6             0.08
  Estimated GFR, ml/min/mm^3^                        59.1 ± 28.0                60 ± 28                      47 ± 21                0.0017
  C‐reactive protein, mg/L                           **7.4 ± 2.8**              **7.5 ± 2.8**                **6.5 ± 1.2**          0.14

Abbreviations: ACE, angiotensin‐converting enzyme; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate.

![Association of heart rate tertiles with 1 year mortality after acute heart failure. Adjusted odds ratio for significant covariates (see text). First tertile taken as referent in each group.](EHF2-7-103-g001){#ehf212530-fig-0001}

###### 

Multivariable predictors of 1 year mortality (heart rate as continuous variables)

  Heart rate at Day 4                      Heart rate at discharge                                                                                        
  ---------------------------------------- ------------------------- ------------ ---------- ---------------------------------------- ------ ------------ ---------
  Age, per 1 year                          0.97                      0.94--1.01   0.26       Age, per 1 year                          1.03   0.98--1.08   0.31
  Heart rate at Day 4, per 1 b.p.m.        1.11                      1.06--1.16   0.000007   Heart rate at discharge, per 1 b.p.m.    1.16   1.08--1.24   0.00004
  Systolic blood pressure, per 1 mmHg      0.98                      0.96--1.00   0.21       Systolic blood pressure, per 1 mmHg      1.00   0.98--1.02   0.91
  COPD, yes versus no                      1.52                      0.47--4.91   0.48       COPD, yes versus no                      0.93   0.24--3.6    0.92
  Ischaemic cardiomyopath, yes versus no   1.49                      0.48--4.62   0.41       Ischaemic cardiomyopath, yes versus no   0.33   0.33--1.22   0.10
  Haemoglobin, per 1 g/dl                  0.45                      0.31--0.65   0.00002    Haemoglobin, per 1 g/dl                  0.56   0.40--0.78   0.0006
  Albumin, per 1 g/L                       0.86                      0.76--0.97   0.015      Albumin, per 1 g/L                       0.82   0.75--0.89   0.02
  NT‐proBNP, per 1 pg/ml                   1.026                     0.97--1.08   0.31       NT‐proBNP, per 1 pg/ml                   1.09   0.91--1.29   0.35
  Estimated GFR, per 1 ml/min/mm^3^        0.96                      0.94--0.98   0.0045     Estimated GFR, per 1 ml/min/mm^3^        0.89   0.85--0.93   0.044

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; NT‐proBNP, N terminal pro brain natriuretic peptide; OR, odds ratio.

Conclusions {#ehf212530-sec-0007}
===========

For the first time, we showed that in patients surviving the acute HF phase, a high HR at Day 4, and at a lesser degree at discharge, but not at admission, was a strong predictor of 1 year mortality. Specifically, HRs exceeding 85 b.p.m. were associated with higher mortality while lower thresholds portended better prognosis. Elevated HR results from sympathetic overactivity and is associated with plaque vulnerability and increased oxygen consumption and reduced diastolic filling times, thus compromising coronary perfusion with induction of myocardial ischemia, and precipitation of rhythm disturbances. Early targeting of elevated HR may therefore represent a complementary therapeutic challenge in these patients.[5](#ehf212530-bib-0005){ref-type="ref"} However, in practice, the main therapeutic goal is not so much to directly modulate the HR but to swiftly manage HF symptoms and the increased sympathetic activity by the rapid initiation of effective HF medical treatment (vasodilator, diuretics, and oxygen). In some cases, continuing a tailored dose of beta‐blocker with a rapid uptitration during the acute HF phase may also be effective.[4](#ehf212530-bib-0004){ref-type="ref"} Noteworthy, the most appropriate HR to target is likely that around Day 4 rather than discharge HR because this latter is probably not associated with clinical benefits.[5](#ehf212530-bib-0005){ref-type="ref"} Our findings highlight opportunities for risk stratification and intervention that will require further investigation.
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